STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] ZYNEX INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Zynex, Inc. reported leadership changes tied to the resignation of Chief Commercial Officer Anna Lucsok. Her resignation was effective October 10, 2025, with separation terms finalized on October 27, 2025.

Under her employment agreement, Ms. Lucsok is entitled to severance, conditioned on her execution, non-revocation, and compliance with a Separation Agreement dated October 27, 2025. The Compensation Committee also approved the accelerated vesting of 60,746 unvested restricted shares previously issued to her, effective as of the Separation Date and subject to the same conditions.

Positive
  • None.
Negative
  • None.

Insights

Routine officer departure with conditioned severance and equity vesting.

The company disclosed the resignation of its Chief Commercial Officer, with separation terms governed by an existing employment agreement. Severance eligibility is contingent on execution, non-revocation, and compliance with a separation agreement dated October 27, 2025.

The board approved accelerated vesting of 60,746 unvested restricted shares previously issued to the executive, effective on the Separation Date. Because these are previously issued restricted shares, this action does not indicate a new share issuance. Overall, this appears administrative and not thesis-changing.

0000846475false00008464752025-10-272025-10-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2025

Zynex, Inc.

(Exact Name of Registrant as Specified in its Charter)

       Nevada       

001-38804

90-0275169

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)

9655 Maroon Circle, Englewood, CO 80112

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (800) 495-6670

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

d

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class

Ticker symbol(s)

Name of each exchange on which
registered

Common Stock, $0.001 par value per share

ZYXI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed in a Current Report on Form 8-K filed by Zynex, Inc. (the “Company”) with the Securities and Exchange Commission on October 14, 2025, Anna Lucsok resigned from her position as Chief Commercial Officer of the Company, effective as of October 10, 2025, at which time Ms. Lucsok was placed on paid leave during the pendency of the negotiation of the terms of her separation, which were finalized on October 27, 2025 (the “Separation Date”).

In connection with her resignation, Ms. Lucsok is entitled to receive the severance payments and benefits set forth in her Employment Agreement with the Company, dated January 27, 2021 (the “Lucsok Employment Agreement”), as described in the Proxy Statement under the heading “Compensation Agreements” and “Payments Made Upon Termination,” subject to and conditioned upon Ms. Lucsok’s execution, non-revocation and continued compliance with the terms of the Separation Agreement and Release of Claims that Ms. Lucsok entered into with the Company, dated October 27, 2025 (the “Lucsok Separation Agreement”).

In addition, on October 20, 2025, the Compensation Committee of the Company’s Board of Directors approved the accelerated vesting of 60,746 unvested restricted shares of the Company’s common stock previously issued to Ms. Lucsok under the Company’s 2017 Stock Option Plan and award agreements thereunder, effective as of the Separation Date and subject to the same conditions as Ms. Lucsok’s receipt of severance benefits under the Lucsok Employment Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ZYNEX, INC.

Dated: October 31, 2025

By:

/s/ Steven Dyson

Name: 

Steven Dyson

Title:

Chief Executive Officer

FAQ

What did Zynex (ZYXI) disclose about leadership changes?

Zynex reported the resignation of Chief Commercial Officer Anna Lucsok, effective October 10, 2025, with separation terms finalized on October 27, 2025.

What severance terms apply to Zynex’s former CCO?

Severance is provided under her January 27, 2021 employment agreement, conditioned on her execution, non-revocation, and compliance with a Separation Agreement dated October 27, 2025.

Did Zynex approve any equity actions related to the departure?

Yes. The Compensation Committee approved accelerated vesting of 60,746 unvested restricted shares, effective as of the Separation Date.

When did the board approve the equity vesting changes at Zynex (ZYXI)?

On October 20, 2025, with effectiveness as of the October 27, 2025 Separation Date.

Are there conditions tied to the accelerated vesting at Zynex?

Yes. The vesting is subject to the same conditions as severance under the employment agreement and the October 27, 2025 Separation Agreement.
Zynex Inc

NASDAQ:ZYXI

ZYXI Rankings

ZYXI Latest News

ZYXI Latest SEC Filings

ZYXI Stock Data

34.84M
15.66M
48.31%
18.33%
11.81%
Medical Distribution
Electromedical & Electrotherapeutic Apparatus
Link
United States
ENGLEWOOD